Vera Therapeutics (VERA) 7th Annual Evercore ISI HealthCONx Conference summary

Clinical development and trial progress

• Phase 2 trial showed atacicept stabilized kidney function in young patients over two years, a first in the field.

• Phase 3 trial is fully enrolled, with primary endpoint data expected in Q2 2025, supporting a BLA filing in the second half of 2025.

• Expansion of development includes phase 2 studies in additional IgA nephropathy populations and adjacent autoimmune kidney diseases.

• Atacicept demonstrated immune modulation without immune suppression, even during COVID-19.

• PIONEER study and other basket studies will provide further data throughout 2025.

Market opportunity and regulatory pathway

• IgA nephropathy market estimated at $6–$10 billion, with 160,000 patients in the US.

• Initial approval likely based on proteinuria reduction, with broader label possible after full approval as proteinuria thresholds are removed.

• Long-term eGFR data may influence future regulatory decisions and label guidance.

• Received breakthrough designation from FDA, enabling frequent engagement with the agency.

Product mechanism and differentiation

• Atacicept is a fusion protein inhibiting both BAFF and APRIL, targeting B cell survival and differentiation.

• Dual inhibition is expected to offer broader efficacy than targeting APRIL or BAFF alone.

• The natural TACI receptor enables binding to both monomeric and multimeric cytokine constructs, potentially offering comprehensive B cell modulation.